Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
ASX RELEASE
18 October 2024
Dear Shareholders
2024 ANNUAL GENERAL MEETING
The Company’s annual general meeting is scheduled to be held at the offices of FB Rice, Level 33,
477 Collins Street, Melbourne VIC 3000, and as a virtual meeting on Tuesday, 19th November
2024 at 11:00am (AEDT) (Meeting), with registration from 10.30am (AEDT).
In accordance with new provisions under the Corporations Act, the Company will not be sending
hard copies of the Notice of Meeting to shareholders unless a shareholder has previously
requested a hard copy. The Notice of Meeting can be viewed and downloaded from
https://paradigmbiopharma.com/performance-progress/ Please also refer to the Online
Meeting Guide attached to the Notice of Meeting for details on how to participate in the
Meeting.
The Company strongly encourages Shareholders to lodge a directed proxy form prior to the
meeting. Questions should also be submitted in advance of the Meeting as this will provide
management with the best opportunity to prepare for the Meeting, for example by preparing
answers in advance to Shareholders questions. However, votes and questions may also be
submitted during the Meeting. Further details of how to participate in the Meeting are set out in
the Online Meeting Guide.
Please find below links to important Meeting documents:
Notice of Meeting and Explanatory Memorandum:
https://paradigmbiopharma.com/performance-progress/
Online Meeting platform:
https://www.automicgroup.com.au/virtual-agms/
Alternatively, a complete copy of the important Meeting documents has been posted on the
Company’s ASX market announcements page.
If you have nominated an email address and have elected to receive electronic communications
from the Company, you will also receive an email to your nominated email address with a link to
an electronic copy of the important Meeting documents.
In order to receive electronic communications from the Company in the future, please update
your Shareholder details online at www.investor.automic.com.au/#/home and log in with your
unique shareholder identification number and postcode (or country for overseas residents),
Paradigm Biopharmaceuticals Ltd | ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
where you can find on your enclosed personalised proxy form. Once logged in you can also lodge
your proxy vote online by clicking on the “Vote” tab.
If you are unable to access any of the important Meeting documents online, please contact the
Company Secretary, Abby Macnish Niven, on +61 8 6382 1805 or via email at
amacnish@paradigmbiopharma.com
The Company
will notify Shareholders via the
Company’s website at
https://paradigmbiopharma.com and the Company’s ASX Announcement Platform at asx.com.au
(ASX:PAR) if changing circumstances impact the planning or arrangements for the Meeting.
This announcement is authorised for market release by the Board of Paradigm
Biopharmaceuticals Limited.
Sincerely,
Abby Macnish Niven
Company Secretary
PARADIGM BIOPHARMACEUTICALS LTD
ACN 169 346 963
NOTICE OF ANNUAL GENERAL MEETING
Notice is given that the Meeting will be held at:
TIME:
11.00am AEDT, registration from 10.30am
DATE:
Tuesday, 19th November 2024
PLACE:
FB Rice, Level 33, 477 Collins Street, Melbourne VIC 3000
and via a virtual meeting
The business of the Meeting affects your shareholding and your vote is important.
This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote,
they should seek advice from their professional advisers prior to voting.
The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001
(Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at
11.00am AEDT on Sunday, 17th November 2024.
BUSINESS OF THE MEETING
AGENDA
1.
FINANCIAL STATEMENTS AND REPORTS
To receive and consider the annual financial report of the Company for the financial year
ended 30 June 2024 together with the declaration of the Directors, the Director’s report,
the Remuneration Report and the auditor’s report.
2.
RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as a non-binding resolution:
“That, for the purposes of section 250R(2) of the Corporations Act and for all other
purposes, approval is given for the adoption of the Remuneration Report as
contained in the Company’s annual financial report for the financial year ended 30
June 2024.”
Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company.
A voting prohibition statement applies to this Resolution. Please see below.
3.
RESOLUTION 2 – SPILL RESOLUTION
If less than 25% of the votes cast on Resolution 1 are voted against adoption of the
Remuneration Report, the Chair will withdraw Resolution 2.
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purposes of section 250V(1) of the Corporations Act and for all other
purposes, approval is given for:
(a)
the Company to hold another meeting of Shareholders within 90 days of
the date of this Meeting (Spill Meeting); and
(b)
all Vacating Directors to cease to hold office immediately before the end
of the Spill Meeting; and
(c)
resolutions to appoint persons to offices that will be vacated pursuant to
(b) to be put to vote at the Spill Meeting.”
A voting prohibition statement applies to this Resolution. Please see below.
4.
RESOLUTION 3 – ELECTION OF MATTHEW FRY
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purpose of clause 13.1(d) of the Constitution, Listing Rule 14.4 and for
all other purposes, Matthew Fry, a Director who was appointed casually on 4 March
2024, retires, and being eligible, is elected as a Director.”
5.
RESOLUTION 4 – RE-ELECTION OF MR AMOS MELTZER
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purpose of clause 13.3 of the Constitution, Listing Rule 14.4 and for all
other purposes, Amos Meltzer, a Director, retires by rotation, and being eligible, is reelected as a Director.”
/1464_7
1
6.
RESOLUTION 5 – ISSUE OF INCENTIVE PERFORMANCE RIGHTS TO DONNA SKERRETT
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is
given for the Company to issue 1,200,000 Performance Rights to Donna Skerrett (or
her nominee) under the Paradigm Employee Performance Rights Plan on the terms
and conditions set out in the Explanatory Statement.”
A voting exclusion statement and voting prohibition statement applies to this Resolution. Please see below.
7.
RESOLUTION 6 – ISSUE OF INCENTIVE PERFORMANCE RIGHTS TO PAUL RENNIE
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is
given for the Company to issue 1,700,000 Performance Rights to Paul Rennie (or his
nominee) under the Paradigm Employee Performance Rights Plan on the terms and
conditions set out in the Explanatory Statement.”
A voting exclusion statement and voting prohibition statement applies to this Resolution. Please see below.
8.
RESOLUTION 7 – RATIFICATION OF PRIOR ISSUE OF OPTIONS TO FIFTYONE CAPITAL
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders
ratify the issue of 2,500,000 Options to FiftyOne Capital Pty Ltd on the terms and
conditions set out in the Explanatory Statement.”
A voting exclusion statement applies to this Resolution. Please see below.
9.
RESOLUTION 8 – APPROVAL OF 7.1A MANDATE
To consider and, if thought fit, to pass the following resolution as a special resolution:
“That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is
given for the Company to issue up to that number of Equity Securities equal to 10%
of the issued capital of the Company at the time of issue, calculated in accordance
with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and
conditions set out in the Explanatory Statement.”
/1464_7
2
Voting Prohibition Statements
Resolution 1 – Adoption of
Remuneration Report
A vote on this Resolution must not be cast (in any capacity) by or on
behalf of either of the following persons:
(a)
a member of the Key Management Personnel, details of whose
remuneration are included in the Remuneration Report; or
(b)
a Closely Related Party of such a member.
However, a person (the voter) described above may cast a vote on this
Resolution as a proxy if the vote is not cast on behalf of a person
described above and either:
(a)
the voter is appointed as a proxy by writing that specifies the
way the proxy is to vote on this Resolution; or
(b)
the voter is the Chair and the appointment of the Chair as
proxy:
(i)
does not specify the way the proxy is to vote on this
Resolution; and
(ii)
expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or
indirectly with the remuneration of a member of the
Key Management Personnel.
Resolution 2 – Spill
Resolution
A vote on this Resolution must not be cast (in any capacity) by or on
behalf of either of the following persons:
(a)
a member of the Key Management Personnel, details of whose
remuneration are included in the Remuneration Report; or
(b)
a Closely Related Party of such a member.
However, a person (the voter) described above may cast a vote on this
Resolution as a proxy if the vote is not cast on behalf of a person
described above and either:
(a)
the voter is appointed as a proxy by writing that specifies the
way the proxy is to vote on this Resolution; or
(b)
the voter is the Chair and the appointment of the Chair as
proxy:
(i)
does not specify the way the proxy is to vote on this
Resolution; and
(ii)
expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or
indirectly with the remuneration of a member of the
Key Management Personnel.
Resolution 5 – Issue of
Incentive Performance
Rights to Dr Donna Skerrett
A person appointed as a proxy must not vote, on the basis of that
appointment, on this Resolution if:
(a)
the proxy is either:
(i)
a member of the Key Management Personnel; or
(ii)
a Closely Related Party of such a member; and
(b)
the appointment does not specify the way the proxy is to vote
on this Resolution.
However, the above prohibition does not apply if:
(a)
the proxy is the Chair; and
(b)
the appointment expressly authorises the Chair to exercise the
proxy even though this Resolution is connected directly or
indirectly with remuneration of a member of the Key
Management Personnel.
/1464_7
3
Resolution 6 – Issue of
Incentive Performance
Rights to Mr Paul Rennie
A person appointed as a proxy must not vote, on the basis of that
appointment, on this Resolution if:
(a)
the proxy is either:
(i)
a member of the Key Management Personnel; or
(ii)
a Closely Related Party of such a member; and
(b)
the appointment does not specify the way the proxy is to vote
on this Resolution.
However, the above prohibition does not apply if:
(a)
the proxy is the Chair; and
(b)
the appointment expressly authorises the Chair to exercise the
proxy even though this Resolution is connected directly or
indirectly with remuneration of a member of the Key
Management Personnel.
Voting Exclusion Statements
In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the
Resolution set out below by or on behalf of the following persons:
Resolution 5 – Issue of
Incentive Performance
Rights to Dr Donna Skerrett
Any person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is
eligible to participate in the employee incentive scheme in question
(including Donna Skerrett) or an associate of that person or those
persons.
Resolution 6 – Issue of
Incentive Performance
Rights to Mr Paul Rennie
Any person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is
eligible to participate in the employee incentive scheme in question
(including Paul Rennie) or an associate of that person or those persons.
Resolution 7 - Ratification of
Prior Issue of Options to
FiftyOne Capital Pty Ltd
FiftyOne Capital Pty Ltd or any other person who participated in the
issue or an associate of that person or those persons.
However, this does not apply to a vote cast in favour of the Resolution by:
(a)
a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with the directions given to the proxy or attorney to vote on the Resolution in that
way; or
(b)
the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with a direction given to the Chair to vote on the Resolution as the Chair decides;
or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of
a beneficiary provided the following conditions are met:
/1464_7
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not
excluded from voting, and is not an associate of a person excluded from voting, on
the Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
4
Voting by proxy
To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in
accordance with the instructions set out on the Proxy Form.
In accordance with section 249L of the Corporations Act, Shareholders are advised that:
•
each Shareholder has a right to appoint a proxy;
•
the proxy need not be a Shareholder of the Company; and
•
a Shareholder who is entitled to cast two or more votes may appoint two proxies and may
specify the proportion or number of votes each proxy is appointed to exercise. If the
Shareholder appoints two proxies and the appointment does not specify the proportion or
number of the member’s votes, then in accordance with section 249X(3) of the
Corporations Act, each proxy may exercise one-half of the votes.
Shareholders and their proxies should be aware that:
•
if proxy holders vote, they must cast all directed proxies as directed; and
•
any directed proxies which are not voted will automatically default to the Chair, who must
vote the proxies as directed.
Voting in person
To vote in person, attend the Meeting at the time, date and place set out above.
In accordance with the Corporations Act, the Company will not be sending hard copies of this
Notice of Meeting to Shareholders, unless a Shareholder has requested a hard copy by Thursday 10
October 2024. This Notice of Meeting can be viewed and downloaded from the link set out below.
Please also refer to the Online Meeting Guide attached to this Notice of Meeting for details on how
to participate in the Meeting.
The Company strongly encourages Shareholder to lodge a directed proxy form prior to the Meeting.
Questions should also be submitted in advance of the Meeting as this will provide management
with the best opportunity to prepare for the Meeting, for example, by preparing answers in advance
to Shareholder questions. However, votes and questions may also be submitted during the Meeting.
Virtual Meeting
The Company is pleased to provide Shareholders with the opportunity to attend and participate in
a virtual Meeting through an online meeting platform powered by Automic, where Shareholders will
be able to watch, listen and vote online.
Shareholders will be able to vote and ask questions at the virtual Meeting. Shareholders are also
encouraged to submit questions in advance of the Meeting to the Company. Questions must be
submitted in writing to Abby Macnish Company Secretary at amacnish@paradigmbiopharma.com
at least 48 hours before the Meeting.
The Company will also provide Shareholders with the opportunity to ask questions during the
Meeting in respect to the formal items of business as well as general questions in respect to the
Company and its business.
Attending the Meeting virtually
To access the virtual Meeting:
1.
Open your internet browser and go to investor.automic.com.au.
2.
Login with your username and password or click “Register” if you haven’t already created
an account. Shareholders are encouraged to create an account prior to the start of the
Meeting to ensure there is no delay in attending the virtual Meeting.
3.
After logging in, a banner will display at the bottom of your screen to indicate that the
Meeting is open for registration. Click on “Register” when this appears. Alternatively, click
on “Meetings” on the left-hand menu bar to access registration.
4.
Click on “Register” and follow the steps.
5.
Click on the URL to join the webcast where you can view and listen to the virtual Meeting.
Note that the webcast will open in a separate window.
/1464_7
5
6.
Once the Chair of the Meeting has declared the poll open for voting click on "Refresh" to
be taken to the voting screen.
7.
Select your voting direction and click "save" to submit your vote. Note that you cannot
amend your vote after it has been submitted.
For further information on the live voting process please see the “Registration and Voting Guide” at
https://www.automicgroup.com.au/virtual-agms/.
The Company will provide Shareholders with the opportunity to vote and ask questions at the
Meeting in respect of the formal items of business as well as general questions in respect to the
Company and its business.
How do I create an account with Automic?
To
create
an account
with
Automic,
please
go to the
Automic
website
(https://investor.automic.com.au/#/home), click on ‘register’ and follow the steps. Shareholders will
require their holder number (Securityholder Reference Number (SRN) or Holder Identification
Number (HIN)) to create an account with Automic.
Further information and support on how to use the platform is available on the share registry website
– www.automic.com.au. It is recommended that you register to use the registry website well in
advance of the Meeting to save time on the day of the Meeting. Should you have any difficulties,
you can contact the registry by telephone on 1300 288 664 (within Australia) and +61 2 9698 5414
(overseas).
You may still attend the Meeting and vote even if you have appointed a proxy. If you have
previously submitted a Proxy Form, your attendance at the Meeting will not revoke your proxy
appointment unless you actually elect to attend as a voting holder at the Meeting for which the
proxy is proposed to be used, in which case, the proxy’s appointment will be deemed to be revoked
with respect to voting.
Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company
Secretary on +61 8 6382 1805.
/1464_7
6
EXPLANATORY STATEMENT
This Explanatory Statement has been prepared to provide information which the Directors believe
to be material to Shareholders in deciding whether or not to pass the Resolutions.
1.
FINANCIAL STATEMENTS AND REPORTS
In accordance with the Corporations Act, the business of the Meeting will include receipt
and consideration of the annual financial report of the Company for the financial year
ended 30 June 2024 together with the declaration of the Directors, the Directors’ report,
the Remuneration Report and the auditor’s report.
The Company will not provide a hard copy of the Company’s annual financial report to
Shareholders unless specifically requested to do so. The Company’s annual financial
report is available on its website at www.paradigmbiopharma.com.
2.
RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT
2.1
General
The Corporations Act requires that at a listed company’s annual general meeting, a
resolution that the remuneration report to be adopted must be put to the shareholders.
However, such a resolution is advisory only and does not bind the company or the directors
of the company.
The remuneration report sets out the company’s remuneration arrangements for the
directors and senior management of the company. The remuneration report is part of the
directors’ report contained in the annual financial report of the company for a financial
year.
The chair of the meeting must allow a reasonable opportunity for its shareholders to ask
questions about or make comments on the remuneration report at the annual general
meeting.
2.2
Voting consequences
A company is required to put to its shareholders a resolution proposing the calling of
another meeting of shareholders to consider the appointment of directors of the company
(Spill Resolution) if, at consecutive annual general meetings, at least 25% of the votes cast
on a remuneration report resolution are voted against adoption of the remuneration report
and at the first of those annual general meetings a Spill Resolution was not put to vote. If
required, the Spill Resolution must be put to vote at the second of those annual general
meetings.
If more than 50% of votes cast are in favour of the Spill Resolution, the company must
convene a shareholder meeting (Spill Meeting) within 90 days of the second annual
general meeting.
All of the directors of the company who were in office when the directors' report (as
included in the company’s annual financial report for the most recent financial year) was
approved, other than the managing director of the company, will cease to hold office
immediately before the end of the Spill Meeting but may stand for re-election at the Spill
Meeting.
Following the Spill Meeting those persons whose election or re-election as directors of the
company is approved will be the directors of the company.
2.3
Previous voting results
At the Company's previous annual general meeting, the votes cast against the
remuneration report considered at that annual general meeting were more than 25%.
Accordingly, the Spill Resolution will be relevant for this Meeting if at least 25% of the votes
cast on this Resolution are voted against adoption of the Remuneration Report. Refer to
Resolution 2 and Section 3 of this Explanatory Statement for further information.
/1464_7
7
3.
RESOLUTION 2 – SPILL RESOLUTION
If less than 25% of the votes cast on Resolution 1 are voted against adoption of the
Remuneration Report, the Chair will withdraw Resolution 2.
3.1
General
The Corporations Act requirements for this Resolution to be put to vote are set out in
Section 2.2.
The effect of this Resolution being passed is the Company will be required to hold another
meeting of Shareholders within 90 days of the date of this Meeting (Spill Meeting) and the
Vacating Directors will cease to hold office immediately before the end of the Spill
Meeting. The business of the Spill Meeting will be to put to vote resolutions to appoint
persons to offices vacated by the Vacating Directors.
In the event a Spill Meeting is required a separate notice of meeting will be distributed to
Shareholders with details about those persons who will seek election as directors of the
Company at the Spill Meeting.
3.2
Proxy voting restrictions
Shareholders appointing a proxy for this Resolution should note the voting restrictions
applying to Resolution 1 apply in the same manner to this Resolution.
4.
RESOLUTION 3 – ELECTION OF MATTHEW FRY
4.1
General
The Constitution allows the Directors to appoint at any time a person to be a Director either
to fill a casual vacancy or as an addition to the existing Directors, but only where the total
number of Directors does not at any time exceed the maximum number specified by the
Constitution.
Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office
only until the next annual general meeting and is then eligible for election by Shareholders
but shall not be taken into account in determining the Directors who are to retire by
rotation (if any) at that meeting.
Matthew Fry, having been appointed by other Directors on 4 March 2024 in accordance
with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4
and being eligible, seeks election from Shareholders.
Further information in relation to Mr Fry is set out below.
Qualifications,
experience and
other material
directorships
Mr Fry has more than 25 years of experience in business creation,
strategy, and expansion in healthcare and medical diagnostics
globally. He is currently the CEO, Managing Director and Founder of
AM Diagnostics Pty Ltd, a manufacturer and distributor of world class
medical diagnostic products.
Mr Fry has significant experience with global regulatory agencies, in
particular the Australian TGA and US FDA. Through his role as
Founder and CEO of AM Diagnostics Pty Ltd, Matthew drove the
company’s expansion into the United States in 2009 and is a leading
biotechnology device supplier with a deep understanding of sales
channels in both the US medical wholesale market and retail
market, and how to negotiate with private health providers.
/1464_7
Term of office
Mr Fry has served as a Director since 4 March 2024.
Independence
If re-elected, the Board considers that Mr Fry will be an independent
Director.
Other material
information
The Company conducts appropriate checks on the background
and experience of candidates before their appointment to the
Board. These include checks as to a person’s experience,
educational qualifications, character, criminal record and
8
bankruptcy history. The Company undertook such checks prior to
the appointment of Mr Fry.
Board
recommendation
4.2
Having received an acknowledgement from Mr Fry that he will have
sufficient time to fulfil their responsibilities as a Director and having
reviewed the performance of Mr Fry since his appointment to the
Board and the skills, knowledge, experience and capabilities
required by the Board, the Directors (other than Mr Fry) recommend
that Shareholders vote in favour of this Resolution.
Technical information required by Listing Rule 14.1A
If this Resolution is passed, Mr Fry will be elected to the Board as an independent Director.
If this Resolution is not passed, Mr Fry will not continue in their role as an independent
Director. The Company may seek nominations or otherwise identify suitably qualified
candidates to join the Company. As an additional consequence, this may detract from
the Board and Company’s ability to execute on its strategic vision.
5.
RESOLUTION 4 – RE-ELECTION OF AMOS MELTZER
5.1
General
Listing Rule 14.4 and clause 13.3 of the Constitution provide that, other than a managing
director, a director of an entity must not hold office (without re-election) past the third
annual general meeting following the director’s appointment or three years, whichever is
the longer. However, where there is more than one managing director, only one is entitled
to be exempt from this rotation requirement.
Amos Meltzer, having held office without re-election since 25 January 2022 and being
eligible, retires by rotation and seeks re-election.
Further information in relation to Mr Meltzer is set out below.
Qualifications,
experience and
other material
directorships
Mr Meltzer is a scientist, intellectual property lawyer and former CEO
and VP of business development with over 25 years of experience
in international trade and in commercialising technologies,
principally in the life sciences sector. He has presided over life
science research and product development projects, clinical trials
as well as the commercialisation of life sciences assets.
Previously, Mr Meltzer served as General Counsel and IP director at
two Nasdaq-listed companies Compugen and Gilat, as a nonexecutive director of a biotechnology company Evogene and as
VP of Business Development and then CEO of an ASX-listed
biopharmaceutical company Immuron.
Mr Meltzer currently serves as Chief Operating Officer (Aust) of
neuro-medical device company Synchron, chairman of the Board
of medicinal cannabis company Connatrek and as a legal advisor
to a number of ASX listed and private life science companies.
/1464_7
Term of office
Mr Meltzer has served as a Director since 9 December 2020 and was
last re-elected on 25 January 2022.
Independence
If re-elected, the Board considers that Mr Meltzer will be an
independent Director.
Board
recommendation
Having received an acknowledgement from Mr Meltzer that he will
have sufficient time to fulfil their responsibilities as a Director and
having reviewed the performance of Mr Meltzer since his
appointment to the Board and the skills, knowledge, experience
and capabilities required by the Board, the Directors (other than Mr
Meltzer) recommend that Shareholders vote in favour of this
Resolution.
9
5.2
Technical information required by Listing Rule 14.1A
If this Resolution is passed, Mr Meltzer will be re-elected to the Board as an independent
Director.
If this Resolution is not passed, Mr Meltzer will not continue in their role as an independent
Director. The Company may seek nominations or otherwise identify suitably qualified
candidates to join the Company. As an additional consequence, this may detract from
the Board and Company’s ability to execute on its strategic vision.
6.
RESOLUTIONS 5 AND 6 – ISSUE OF INCENTIVE PERFORMANCE RIGHTS TO DIRECTORS – DONNA
SKERRETT AND PAUL RENNIE
6.1
General
The Company has agreed, subject to obtaining Shareholder approval, to issue an
aggregate of 2,900,000 Performance Rights to Donna Skerrett and Paul Rennie (together,
the Related Parties), comprising:
(a)
1,200,000 Performance Rights to Donna Skerrett (or her nominee) (the subject of
Reso
Share your feedback
Discover